statement
중국발 공급 증가와 경쟁 심화로 바이오 실적 부진이 장기화되며 주가가 약세를 보였다.
A statement by 신한생각. Statements are as reported by the cited publishers — not verified by DecisionGateway.
중국발 공급 증가와 경쟁 심화로 바이오 실적 부진 장기화되며 주가 약세.
Discussion
Related claims
Chinese stocks rose together in Shanghai, Shenzhen and Hong Kong, driven by strength in AI semiconductor stocks and improved sentiment from falling international oil prices.Hana Global Guru Eye · statement백화점 사업 성장률 둔화 및 외국인 매출 증가세 약화는 주가에 부담 요인이다.리포트 작성자 · statementFrom 4Q onward, price increase effects, overseas coverage expansion, and securing bio cost competitiveness through collaboration with ADM are expected.report author · prediction문제는 중국 MLB 재고 건전화를 위한 출고 조정으로 중국법인 매출 부진 지속 중. 마진율이 높은 중국향 유통 매출의 감소로 영업이익 하락세가 예상 수준을 초과.신한생각 · statementKOSPI turned weak as AI investment sentiment contracted due to successive U.S. big tech corporate bond issuance news and Anthropic's financial burden, and caution ahead of the U.S. midterm elections also limited risk asset preference.FICC리서치부 전략/시황: 이경민 · statementThe semiconductor sector succeeded in rebounding on bargain hunting, while other sectors continued to weaken amid deteriorated investment sentiment, producing sector-specific divergence.FICC리서치부 전략/시황: 이경민 · statement
More claims by 신한생각
The game segment saw domestic mobile strength from webboard revenue and Chuseok effects despite the high base of Japanese mobile games in the prior quarter.statementThe payment segment set record highs, with NHN KCP transaction value of 17.3 trillion won and overseas merchant transaction share of 25.3%.statementThe investment opinion 'Buy' is maintained and the target price is raised 19.2% to 94,000 won, applying a target multiple of 18x to 12-month forward EPS of 4,858 won.statementThe 27F AI DC revenue is estimated at 190.8 billion won and operating profit at 46 billion won.predictionNHN will build 1,700 B300 units through a new capital-area base, with service scheduled to begin in January 2027.statement
All claims by 신한생각